<DOC>
	<DOCNO>NCT02527434</DOCNO>
	<brief_summary>A Phase II , Multi-Center , Open-Label Study Tremelimumab Monotherapy Patients Advanced Solid Tumors</brief_summary>
	<brief_title>Study Tremelimumab Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label , multi-center study determine efficacy safety tremelimumab treatment different cohort patient select advanced solid tumor . If eligible discretion Investigator , confirm disease progression tremelimumab monotherapy follow-up , patient option sequence MEDI4736 ( MedImmune 4736 ) monotherapy MEDI4736 + tremelimumab combination therapy , 12 month disease progression , whichever come sooner .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1. histologically cytologically document solid tumor malignancy , include limited 1 following : UBC , Metastatic PDAC , TNBC ; Are intolerant , ineligible , refuse treatment standard firstline therapy ; 2 . At least 1 lesion , previously irradiate , accurately measure baseline ≥10 mm long diameter ( except lymph node , must short axis ≥15 mm ) compute tomography ( CT ) ( prefer ) magnetic resonance imaging ( MRI ) scan suitable accurate repeat measurement . Exclusion criterion : 1 . Any concurrent chemotherapy , biologic , hormonal therapy cancer Treatment ; 2 . History leptomeningeal carcinomatosis ; 3 . Active prior document autoimmune inflammatory disorder ; 4 . Brain metastasis spinal cord compression unless asymptomatic treat stable steroid anticonvulsant least 14 day prior study treatment start ; 5 . QT interval correct heart rate use Fridericia 's formula ( QTcF ) ≥470 m ; 6 . Known allergy hypersensitivity IP IP excipient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Urothelial bladder cancer , Triple-negative breast cancer , Pancreatic ductal adenocarcinoma , Advanced Solid Tumors , Tremelimumab , MEDI4736 , ORR</keyword>
</DOC>